Rationale and Design of the German-Speaking Myeloma Multicenter Group (GMMG) Trial HD6: A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction/Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma

BMC Cancer - United Kingdom
doi 10.1186/s12885-019-5600-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Lenalidomide−prednisone Induction Followed by Lenalidomide−melphalan−prednisone Consolidation and Lenalidomide−prednisone Maintenance in Newly Diagnosed Elderly Unfit Myeloma Patients

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2012English

Benefit of Continuous Treatment for Responders With Newly Diagnosed Multiple Myeloma in the Randomized FIRST Trial

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2017English

Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2006English

Phase I/Ii Multicenter Clinical Trial of Lenalidomide Maintenance After Allogeneic Hematopoietic Cell Transplant (alloHCT) in Patients With High Risk (HR) Multiple Myeloma (MM)

Biology of Blood and Marrow Transplantation
TransplantationHematology
2013English

Induction Therapy and Stem Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma

Stem Cells International
Cell BiologyMolecular Biology
2012English

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Response-Adapted Intensification With Cyclophosphamide, Bortezomib, and Dexamethasone Versus No Intensification in Patients With Newly Diagnosed Multiple Myeloma (Myeloma XI): A Multicentre, Open-Label, Randomised, Phase 3 Trial

The Lancet Haematology
Hematology
2019English

The Impact of ASCT on Patients With Newly Diagnosed Multiple Myeloma Who Receive RVD Induction

Journal of Hematological Malignancies
2013English

Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide–CCI-779 Interaction via P-Glycoprotein

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy